Alnylam Pharmaceuticals reports again on August 6 — just one week after the 28% collapse that made its July 30 print one of the most punishing single-day moves in the stock's history.
The options market is telling a notably bullish story into this follow-on event, which is striking given the backdrop. The put/call ratio has dropped to 0.47, more than two and a half standard deviations below its 20-day average of 0.56 — the most call-heavy positioning in the past year. That is unusual for a stock that has lost nearly half its value year-to-date and is still down 21% on the week heading into the print. The setup suggests options traders are leaning into a recovery rather than hedging further downside, though the borrow market offers no corroborating pressure: availability is effectively unlimited at over 5,200% of short interest, cost to borrow has fallen 26% over the week to just 0.40%, and short interest at 4.3% of the float is moderate and barely changed. There is no squeeze dynamic here — shorts face no structural pressure.
The analyst community has moved quickly to recalibrate after the July 30 shock. Every major firm that updated targets last week cut, with Morgan Stanley trimming to $300, Barclays dropping to $450, JP Morgan to $375, and RBC Capital to $350 — yet all held their ratings. Then, on August 3, Raymond James went further and upgraded to Strong Buy, while Citigroup lowered its target to $340 from $380 while staying at Buy. The consensus mean target now sits at $380, against a current price of $220 — implying the Street collectively sees around 73% upside from here. Bulls rest their case on the TTR franchise's long-term revenue potential and Novartis and Sanofi partnerships for RNAi-based treatments. Bears point to AMVUTTRA adoption rates trailing expectations, pipeline delays, and pricing and reimbursement risk. The analyst divergence is less about direction — nearly everyone is still formally positive — and more about how badly the near-term execution stumbled and whether management's revised guidance is credible.
The ownership picture adds one more dimension. T. Rowe Price added over 3.1 million shares in the most recently reported quarter, a meaningful conviction add. Capital Research remains the largest holder at 15.2% of shares, and FMR increased its position by 762,000 shares. That institutional buying sits alongside a stock that has now partially retraced — closing Monday at $220, up 7.2% on the day — having found at least temporary support after the post-earnings lows around $200.
The August 6 print is therefore less about the top-line trajectory that ALNY has already telegraphed and more about whether management can provide enough detail on AMVUTTRA ramp timing and pipeline milestones to justify the Street's collective decision to hold ratings through one of biotech's sharper single-stock dislocations this year.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
